The FDA is moving toward reconsidering restrictions on compounded “popular peptides,” setting up advisory panel review sessions as the agency evaluates whether a handful of peptide products should be allowed through compounding pathways. The decision comes amid growing public and political attention on peptide use. In parallel, the FDA’s communications suggest it is looking at whether certain peptides can be removed from a high-risk category reserved for customized drugs, following earlier moves that added many peptides to compounding restriction lists. The advisory process is expected to occur over multiple meetings during 2026. For biotech and pharma, the FDA’s approach will be closely watched for how it balances safety concerns—especially limited human data—against pressure to expand access to compounded alternatives.